CELC

SEC filing CELC Reports 48.9% ORR, 11.1-Month PFS, HR=0.50 in VIKTORIA-1 Breast Cancer Trial

5h ago

SEC filing CELC Appoints Charles Romp as Independent Director, Adds to Compensation and N&CG Committees, Grants 215 Restricted Shares

13d ago

News Why Celcuity Stock Popped Today

14d ago

SEC filing CELC Stockholders Approve 2026 Stock Incentive Plan with 3M Shares, Amended ESPP with 289K Additional Shares

14d ago

News Celcuity outlines VIKTORIA-2 expansion while targeting July 17 FDA decision for gedatolisib

18d ago

Insider trade Sale by Richard E Buller

26d ago

Insider trade Sale by David Dalvey

26d ago

SEC filing CELC Reports $1.2B Revenue, $0.45 EPS, +85% YoY, Announces $2.1B VIKTORIA-1 Trial Success

31d ago

News Celcuity outlines potential $2.5B annual peak revenue for gedatolisib amid pivotal clinical milestones and commercial launch preparations

68d ago

SEC filing CELC Reports $1.2M Q4 Rev, $0.01 EPS, FDA Accepts NDA for Gedatolisib, Priority Review July 2026, VIKTORIA-1 Topline Data Q2 2026

68d ago

News Inside One Fund's $170 Million Bet on a Biotech Stock Up 1,040% in a Year Amid FDA Review for Breast Cancer Drug

81d ago

Insider trade Sale by David Dalvey

104d ago

News Director Sells 20,000 Celcuity Shares for $2.4 Million Following 933% Share Price Jump

115d ago

News Adani Flagship Posts Record Profit on One-Time Gain

119d ago

Scanner Unusual volume (z=5.3)

160d ago

Scanner Unusual volume (z=5.1)

161d ago

Scanner Unusual volume (z=5.1)

163d ago

Scanner Unusual volume (z=5.1)

164d ago